Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Ocugen
< Previous
1
2
3
4
5
Next >
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
April 01, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
April 01, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
March 18, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
March 13, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Present at Investing in Cures Summit
March 06, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Clinical Showcase Webcast Now Available
February 28, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
February 22, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Present at 2024 BIO CEO & Investor Conference
February 21, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
February 14, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Present at Pharma Market Research Conference
January 31, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
January 16, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design
December 21, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations
December 19, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
December 13, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
November 29, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
November 10, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Provides Business Update with Third Quarter 2023 Financial Results
November 09, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit
November 07, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results
November 02, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
October 10, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa
October 04, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
September 29, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
September 27, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
September 21, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023
September 20, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
September 13, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
September 12, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Provides Business Update with Second Quarter 2023 Financial Results
August 21, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results
August 18, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly
June 30, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
